Skip to main content
Fig. 3 | Journal of Hematology & Oncology

Fig. 3

From: Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002)

Fig. 3

a Kaplan–Meier estimated duration of response in full analysis set population based on an independent radiological review committee (IRRC) assessment of patients (N = 36). b Kaplan–Meier estimated progression-free survival in full analysis set population based on an IRRC assessment (N = 89). NR, not reached; CI, confidence interval

Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us